A Phase 3 interventional study of Everolimus and Placebo in Advanced NET of GI Origin, Advanced NET of Lung Origin and Neuroendocrine Tumors, sponsored by Novartis Pharmaceuticals. Completed at 97 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing everolimus in Neuroendocrine Tumors — 1 open to participants now, 2 under way, none of them phase 3. Everolimus · Neuroendocrine Tumors.
Among the 22 studies testing everolimus in Neuroendocrine Tumors, this one has the largest enrollment, is one of 4 that started in 2012, is one of 2 in phase 3, and was the 10th registered.
543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.
Browse Neuroendocrine Tumors studies →1 of the 22 studies testing everolimus in Neuroendocrine Tumors is open now, in 1 country. Recruiting first, the newest first:
AC Camargo Cancer Center · Sites in Brazil
Ages 16+
By country, each count listing its studies:
Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 11 · Phase 3 2 · Phase 4 3
First in 2006; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 41 across 387 interventional studies indexed under Neuroendocrine Tumors.
Median enrollment 38 across the 22 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
18 studies in Neuroendocrine Tumors by Novartis: none open now, 1 under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 18 studies in Neuroendocrine Tumors by Novartis, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2012, is one of 2 in phase 3, and was the 7th registered.
Novartis’s Neuroendocrine Tumors studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing everolimus in Neuroendocrine Tumors, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 18 in Neuroendocrine Tumors:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of carcinoid syndrome.
This was a prospective, multi-center, randomized, double-blind, parallel-group, placebo-controlled, two-arm Phase III study comparing the efficacy and safety of everolimus 10 mg daily to placebo in patients with advanced NET of GI or lung origin without a history of, or current symptoms of carcinoid syndrome.
After assessment of eligibility, participants qualifying for the study were randomized in a 2:1 ratio to receive either everolimus or matching placebo. Participants received daily oral doses of 10 mg everolimus or matching placebo as study drug. In both arms, the study drug was combined with best supportive care and treatment cycles were defined as 28 days. Participants were treated until disease progression as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.0, intolerable toxicity, death, lost to follow-up or consent withdrawal. Regardless of the reason for study drug discontinuation, participants had a safety follow-up visit scheduled 30 days after the last dose of the study drug.
Per data monitoring committee recommendation, all participants on treatment with placebo were allowed to crossover to open-label treatment with everolimus. This change was implemented through protocol amendment 3 (issued on 06-May-2016) after which remaining participants entered into open-label phase of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who had any severe and/or uncontrolled medical conditions such as:
Other protocol-defined inclusion/exclusion criteria might apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received everolimus 10 mg once daily plus best supportive care (BSC) throughout the study
Drug: Everolimus · Other: Best suportive care (BSC)
Participants received matching placebo once daily plus best supportive care (BSC) during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period.
Drug: Placebo · Other: Best suportive care (BSC)
Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken
Also known as: RAD001
Participants were treated with two tablets of matching placebo once daily orally taken.
Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment
PFS is defined as the time from randomization to the date of the first documented tumor progression or death from any cause, whichever comes first. Progression was defined using modified RECIST 1.0 and as per central radiology assessment as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. Progression was assessed by cat scan (CT) and/or magnetic resonance imaging (MRI). For participants who had not progressed or died at the analysis cut-off date, PFS was censored at the date of the last adequate tumor evaluation date. An adequate tumour assessment is a tumour assessment with an overall response other than unknown. The percentage event-free probability estimate is the estimated probability that a patient will remain event-free in PFS up to the specified time point.
Time frame: From date of randomization to progression or death, whichever comes first, assessed up to 27 months
Overall Survival (OS)
OS is defined as the time from the date of randomization to date of death due to any cause. If a death had not been observed by the date of analysis cut-off, then OS was censored at the date of last contact. All participants randomized to placebo arm who crossed over to everolimus were censored.
Time frame: From date of randomization to date of death, assessed up to approximately 8 years
Overall Response Rate (ORR) as Per Modified RECIST 1.0 According to Central Evaluation
ORR is defined as the proportion of patients with best overall response (BOR) of complete response (CR) or partial response (PR), according to central evaluation and as per modified RECIST 1.0. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.
Time frame: From randomization until end of treatment, assessed up to approximately 2.5 years
Disease Control Rate (DCR) Based on Modified RECIST 1.0 and as Per Central Radiology Assessment
DCR is defined as the proportion of subjects with best overall response of CR or PR or stable disease based on modified RECIST 1.0 and as per central radiology assessment. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. Stable disease: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression.
Time frame: From randomization until end of treatment, assessed up to approximately 2.5 years
Time to Definitive Deterioration in Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire Total Score
FACT-G is a self-assessed health-related quality of life questionnaire. The questionnaire is comprised of 27 questions examining physical, social/family, emotional, and functional well-being. Participants responded to the items on a five-point scale, ranging from 0: "Not at all" to 4: "Very much." The total score ranges from 0 to 108, with higher scores indicating a better patient-reported outcome/quality of life. Definitive deterioration is defined as a decrease in the total score by at least 7 points compared to baseline with no further improvement. Death was considered as worsening of the FACT-G total score if it occurred close to the last available assessment, where "close" was defined as twice the planned period between two assessments. Patients without definitive worsening prior to analysis cut-off or prior to start of another anticancer therapy were censored at the date of their last assessment.
Time frame: From randomization to definitive deterioration of FACT-G total score, assessed up to approximately 3 years
Change From Baseline in Chromogranin A (CgA) Levels
CgA is a potential biomarker for tumor response. Blood samples were collected for assessment of CgA levels. Change from Baseline at a particular visit was calculated as the CgA level at that visit minus Baseline.
Time frame: From baseline (every 4 weeks) up to 116 weeks
Change From Baseline in Neuron Specific Enolase (NSE) Levels
NSE is a potential biomarker for tumor response. Blood samples were collected for assessment of NSE levels. Change from Baseline at a particular visit was calculated as the NSE level at that visit minus Baseline.
Time frame: From baseline (every 4 weeks) up to Week 116
Time to Definitive Deterioration in World Health Organization (WHO) Performance Status (PS) Change
WHO PS is a scale rated from 0 (fully active) to 5 (death) by a healthcare professional to assess the overall status of a patient: a lower score represents a higher ability to perform daily tasks. Deterioration is defined as an increase of at least one point compared to baseline. Deterioration is considered definitive if no improvements in the WHO PS status is observed at a subsequent time of measurement during the treatment period following the time point where the deterioration is observed. Death was considered as worsening of the WHO PS if it occurred close to the last available assessment, where "close" was defined as twice the planned period between two assessments. Patients without definitive worsening prior to analysis cut-off or prior to start of another anticancer therapy were censored at the date of their last assessment.
Time frame: From randomization to definitive deterioration of WHO performance status, assessed up to approximately 3 years
Pharmacokinetics (PK): Predose Concentration (Cmin) of Everolimus at Day 29
A pre-dose blood sample at day 29 was collected to determine the exposure of everolimus at the steady-state pre-dose concentration (Cmin). Cmin is provided for participants randomized to everolimus+BSC who received 10mg of everolimus daily and also for participants randomized to everolimus+BSC who received 5mg of everolimus daily which was required for a number of participants in the study experiencing adverse events requiring dose modifications
Time frame: Pre-dose at Day 29.
| Milestone | Everolimus + BSC (Throughout Study) | Placebo+BSC (Blinded Period) | Everolimus+BSC (Crossover) |
|---|---|---|---|
| Started | 205 | 97 | 0 |
| Completed | 26 | 6 | 0 |
| Not completed | 179 | 91 | 0 |
| Withdrew: Adverse event | 64 | 7 | 0 |
| Withdrew: Disease progression | 89 | 75 | 0 |
| Withdrew: Withdrawal by subject | 19 | 6 | 0 |
| Withdrew: Protocol deviation | 2 | 1 | 0 |
| Withdrew: Death | 5 | 2 | 0 |
| Milestone | Everolimus + BSC (Throughout Study) | Placebo+BSC (Blinded Period) | Everolimus+BSC (Crossover) |
|---|---|---|---|
| Started | 26 | 0 | 6 |
| Completed | 0 | 0 | 0 |
| Not completed | 26 | 0 | 6 |
| Withdrew: Disease progression | 13 | 0 | 2 |
| Withdrew: Administrative problems | 5 | 0 | 2 |
| Withdrew: Adverse event | 5 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
PFS is defined as the time from randomization to the date of the first documented tumor progression or death from any cause, whichever comes first. Progression was defined using modified RECIST 1.0 and as per central radiology assessment as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. Progression was assessed by cat scan (CT) and/or magnetic resonance imaging (MRI). For participants who had not progressed or died at the analysis cut-off date, PFS was censored at the date of the last adequate tumor evaluation date. An adequate tumour assessment is a tumour assessment with an overall response other than unknown. The percentage event-free probability estimate is the estimated probability that a patient will remain event-free in PFS up to the specified time point.
| Percent event-free probability in PFS | Everolimus + BSC | Placebo + BSC |
|---|---|---|
| 2 months | 90.1 (84.8 to 93.5) | 74.6 (64.3 to 82.4) |
| 4 months | 81.2 (74.9 to 86.2) | 49.1 (38.1 to 59.2) |
| 6 months | 72.1 (65.0 to 78.0) | 40.1 (29.5 to 50.5) |
| 8 months | 62.4 (54.8 to 69.1) | 35.8 (25.4 to 46.2) |
| 10 months | 51.7 (44.0 to 59.0) | 31.3 (21.3 to 41.7) |
| 12 months | 44.4 (36.7 to 51.8) | 28.1 (18.5 to 38.6) |
| 15 months | 40.1 (32.5 to 47.6) | 26.4 (16.9 to 36.8) |
| 18 months | 31.8 (24.1 to 39.8) | 24.4 (15.0 to 34.9) |
| 21 months | 27.6 (19.0 to 36.8) | 17.4 (9.0 to 28.2) |
| 24 months | 22.0 (13.0 to 32.5) | 17.4 (9.0 to 28.2) |
| 27 months | NA (NA to NA) | 17.4 (9.0 to 28.2) |
OS is defined as the time from the date of randomization to date of death due to any cause. If a death had not been observed by the date of analysis cut-off, then OS was censored at the date of last contact. All participants randomized to placebo arm who crossed over to everolimus were censored.
| Months | Everolimus + BSC | Placebo + BSC |
|---|---|---|
| Overall Survival (OS) | 43.1 (36.27 to 54.24) | 41.76 (23.46 to 53.75) |
ORR is defined as the proportion of patients with best overall response (BOR) of complete response (CR) or partial response (PR), according to central evaluation and as per modified RECIST 1.0. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.
| Percentage of participants | Everolimus + BSC | Placebo + BSC |
|---|---|---|
| Overall Response Rate (ORR) as Per Modified RECIST 1.0 According to Central Evaluation | 2.0 (0.5 to 4.9) | 1.0 (0.0 to 5.6) |
DCR is defined as the proportion of subjects with best overall response of CR or PR or stable disease based on modified RECIST 1.0 and as per central radiology assessment. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. Stable disease: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression.
| Percentage of participants | Everolimus + BSC | Placebo + BSC |
|---|---|---|
| Disease Control Rate (DCR) Based on Modified RECIST 1.0 and as Per Central Radiology Assessment | 82.4 (76.5 to 87.4) | 64.9 (54.6 to 74.4) |
FACT-G is a self-assessed health-related quality of life questionnaire. The questionnaire is comprised of 27 questions examining physical, social/family, emotional, and functional well-being. Participants responded to the items on a five-point scale, ranging from 0: "Not at all" to 4: "Very much." The total score ranges from 0 to 108, with higher scores indicating a better patient-reported outcome/quality of life. Definitive deterioration is defined as a decrease in the total score by at least 7 points compared to baseline with no further improvement. Death was considered as worsening of the FACT-G total score if it occurred close to the last available assessment, where "close" was defined as twice the planned period between two assessments. Patients without definitive worsening prior to analysis cut-off or prior to start of another anticancer therapy were censored at the date of their last assessment.
| Months | Everolimus + BSC | Placebo + BSC |
|---|---|---|
| Time to Definitive Deterioration in Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire Total Score | 13.01 (9.33 to 24.80) | 9.23 (5.52 to 28.62) |
CgA is a potential biomarker for tumor response. Blood samples were collected for assessment of CgA levels. Change from Baseline at a particular visit was calculated as the CgA level at that visit minus Baseline.
| microgram/liter (ug/L) | Everolimus + BSC | Placebo + BSC |
|---|---|---|
| Week 4 | 434.8 ± 2306.70 | 1154.3 ± 9083.39 |
| Week 8 | 162.3 ± 2550.65 | 2697.6 ± 19956.90 |
| Week 12 | 396.7 ± 2401.78 | 1176.0 ± 3322.13 |
| Week 16 | 263.5 ± 2946.76 | 1450.4 ± 4825.78 |
| Week 20 | 162.1 ± 2464.47 | 3640.1 ± 12653.42 |
| Week 24 | 253.2 ± 3487.27 | 1783.9 ± 5399.98 |
| Week 28 | 587.2 ± 4861.35 | 1350.3 ± 5701.70 |
| Week 32 | 508.5 ± 6102.61 | 2000.7 ± 6362.83 |
| Week 36 | 94.7 ± 4905.17 | 180.9 ± 383.93 |
| Week 40 | 511.4 ± 6180.67 | 207.6 ± 403.30 |
| Week 44 | 552.8 ± 4173.44 | 140.6 ± 328.02 |
| Week 48 | 1326.2 ± 8718.92 | 129.0 ± 326.69 |
| Week 52 | 1196.2 ± 7737.76 | 124.2 ± 452.38 |
| Week 56 | 1920.6 ± 11250.07 | 134.9 ± 346.33 |
| Week 60 | 1722.0 ± 13155.03 | 120.9 ± 415.73 |
| Week 64 | 3811.0 ± 26656.45 | 141.6 ± 281.38 |
| Week 68 | 1413.3 ± 9588.68 | 222.6 ± 333.93 |
| Week 72 | 239.5 ± 2318.79 | 233.7 ± 400.43 |
| Week 76 | 3256.5 ± 19395.40 | 210.9 ± 522.62 |
| Week 80 | 5421.0 ± 32471.22 | 286.3 ± 425.45 |
| Week 84 | 4379.9 ± 28302.84 | 175.4 ± 575.98 |
| Week 88 | 571.2 ± 2694.44 | -9.4 ± 473.66 |
| Week 92 | 765.5 ± 2913.15 | 63.7 ± 477.53 |
| Week 96 | 984.6 ± 3379.28 | 146.5 ± 468.24 |
| Week 100 | 935.3 ± 2961.60 | -12.7 ± 399.25 |
| Week 104 | 1466.4 ± 4257.03 | -21.7 ± 285.99 |
| Week 108 | 2245.8 ± 6077.99 | 215.9 ± 293.87 |
| Week 112 | 2817.0 ± 7786.28 | 514.5 ± 661.80 |
| Week 116 | 2951.8 ± 6745.06 | 99.6 ± 92.91 |
NSE is a potential biomarker for tumor response. Blood samples were collected for assessment of NSE levels. Change from Baseline at a particular visit was calculated as the NSE level at that visit minus Baseline.
| microgram/liter (ug/L) | Everolimus + BSC | Placebo + BSC |
|---|---|---|
| Week 4 | 0.1 ± 5.21 | -2.2 ± 39.87 |
| Week 8 | 0.3 ± 8.71 | -4.2 ± 36.71 |
| Week 12 | -0.3 ± 8.37 | 15.5 ± 163.75 |
| Week 16 | 2.0 ± 8.34 | 4.1 ± 19.44 |
| Week 20 | 0.8 ± 6.21 | 5.3 ± 18.26 |
| Week 24 | 1.7 ± 8.99 | 6.7 ± 23.47 |
| Week 28 | 1.1 ± 6.37 | 0.4 ± 9.16 |
| Week 32 | 1.5 ± 14.24 | 3.1 ± 8.96 |
| Week 36 | 2.0 ± 15.11 | 2.0 ± 5.90 |
| Week 40 | 1.2 ± 6.48 | 1.2 ± 4.49 |
| Week 44 | 0.8 ± 5.10 | 1.2 ± 4.46 |
| Week 48 | 2.0 ± 9.20 | 0.6 ± 4.06 |
| Week 52 | 1.5 ± 5.82 | 0.7 ± 4.19 |
| Week 56 | 3.6 ± 18.56 | 0.9 ± 5.89 |
| Week 60 | 2.4 ± 8.19 | 0.1 ± 3.35 |
| Week 64 | 4.4 ± 23.22 | 0.9 ± 3.80 |
| Week 68 | 1.1 ± 4.68 | 1.9 ± 4.48 |
| Week 72 | 1.6 ± 4.46 | 0.7 ± 3.91 |
| Week 76 | 1.7 ± 5.11 | 0.6 ± 3.89 |
| Week 80 | 2.9 ± 10.15 | 0.7 ± 2.83 |
| Week 84 | 8.0 ± 33.13 | 0.1 ± 3.47 |
| Week 88 | 2.2 ± 3.89 | 0.6 ± 2.47 |
| Week 92 | 4.0 ± 7.24 | 0.1 ± 3.79 |
| Week 96 | 4.3 ± 5.96 | 0.0 ± 2.99 |
| Week 100 | 1.8 ± 3.79 | -0.2 ± 5.10 |
| Week 104 | 2.9 ± 4.11 | -1.7 ± 4.76 |
| Week 108 | 5.5 ± 13.48 | -0.5 ± 4.33 |
| Week 112 | 2.8 ± 5.72 | -3.2 ± 3.30 |
| Week 116 | 10.6 ± 14.92 | 0.2 ± 4.17 |
WHO PS is a scale rated from 0 (fully active) to 5 (death) by a healthcare professional to assess the overall status of a patient: a lower score represents a higher ability to perform daily tasks. Deterioration is defined as an increase of at least one point compared to baseline. Deterioration is considered definitive if no improvements in the WHO PS status is observed at a subsequent time of measurement during the treatment period following the time point where the deterioration is observed. Death was considered as worsening of the WHO PS if it occurred close to the last available assessment, where "close" was defined as twice the planned period between two assessments. Patients without definitive worsening prior to analysis cut-off or prior to start of another anticancer therapy were censored at the date of their last assessment.
| Months | Everolimus + BSC | Placebo + BSC |
|---|---|---|
| Time to Definitive Deterioration in World Health Organization (WHO) Performance Status (PS) Change | 24.08 (17.05 to NA) | 24.15 (8.31 to NA) |
A pre-dose blood sample at day 29 was collected to determine the exposure of everolimus at the steady-state pre-dose concentration (Cmin). Cmin is provided for participants randomized to everolimus+BSC who received 10mg of everolimus daily and also for participants randomized to everolimus+BSC who received 5mg of everolimus daily which was required for a number of participants in the study experiencing adverse events requiring dose modifications
| nanogram/milliliter (ng/mL) | Everolimus + BSC |
|---|---|
| 10mg daily dose | 16.382 ± 13.2767 |
| 5mg daily dose | 4.700 ± 3.8396 |
Deaths on-treatment were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approximately 8 years. Total Deaths were collected from first dose of study treatment until end of post-treatment survival follow, up to maximum duration of approximately 8 years.
| Participants | Everolimus + BSC (Throughout the Study) | Everolimus +BSC (Crossover) | Everolimus+BSC (All) | Placebo + BSC (Blinded Period) |
|---|---|---|---|---|
| On-treatment deaths | 10 | 0 | 10 | 5 |
| Total deaths | 126 | 1 | 127 | 57 |
Collected over Adverse events and all-cause mortality were collected from date of first dose of study treatment until end of study treatment plus 30 days post treatment, assessed up to a maximum duration of approximately 8 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus+BSC (Throughout Study) | 10/202 (5%) | 93/202 (46%) | 197/202 (97.5%) |
| Everolimus +BSC (Crossover) | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Everolimus+BSC (All) | 10/208 (4.8%) | 94/208 (45.2%) | 203/208 (97.6%) |
| Placebo+BSC (Blinded Period) | 5/98 (5.1%) | 21/98 (21.4%) | 81/98 (82.7%) |
| Event | Everolimus+BSC (Throughout Study) | Everolimus +BSC (Crossover) | Everolimus+BSC (All) | Placebo+BSC (Blinded Period) |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 13/202 | 1/6 | 14/208 | 4/98 |
| Small intestinal obstructionGastrointestinal disorders | 6/202 | 1/6 | 7/208 | 0/98 |
| HypokalaemiaMetabolism and nutrition disorders | 3/202 | 1/6 | 4/208 | 0/98 |
| PyrexiaGeneral disorders | 11/202 | 0/6 | 11/208 | 1/98 |
| DiarrhoeaGastrointestinal disorders | 10/202 | 0/6 | 10/208 | 0/98 |
| AnaemiaBlood and lymphatic system disorders | 7/202 | 0/6 | 7/208 | 0/98 |
| FatigueGeneral disorders | 7/202 | 0/6 | 7/208 | 0/98 |
| PneumoniaInfections and infestations | 7/202 | 0/6 | 7/208 | 1/98 |
| Acute kidney injuryRenal and urinary disorders | 4/202 | 0/6 | 4/208 | 3/98 |
| AstheniaGeneral disorders | 6/202 | 0/6 | 6/208 | 0/98 |
| Event | Everolimus+BSC (Throughout Study) | Everolimus +BSC (Crossover) | Everolimus+BSC (All) | Placebo+BSC (Blinded Period) |
|---|---|---|---|---|
| StomatitisGastrointestinal disorders | 113/202 | 2/6 | 115/208 | 19/98 |
| Aphthous ulcerGastrointestinal disorders | 8/202 | 3/6 | 11/208 | 2/98 |
| DiarrhoeaGastrointestinal disorders | 88/202 | 3/6 | 91/208 | 30/98 |
| HypokalaemiaMetabolism and nutrition disorders | 21/202 | 3/6 | 24/208 | 4/98 |
| RashSkin and subcutaneous tissue disorders | 62/202 | 3/6 | 65/208 | 9/98 |
| Oedema peripheralGeneral disorders | 81/202 | 1/6 | 82/208 | 5/98 |
| FatigueGeneral disorders | 76/202 | 2/6 | 78/208 | 36/98 |
| VertigoEar and labyrinth disorders | 3/202 | 2/6 | 5/208 | 2/98 |
| ConstipationGastrointestinal disorders | 25/202 | 2/6 | 27/208 | 19/98 |
| ToothacheGastrointestinal disorders | 11/202 | 2/6 | 13/208 | 3/98 |
| Age, Continuous(years) | Everolimus + BSC | Placebo+BSC | Total |
|---|---|---|---|
| Mean | 62.9 ± 11.70 | 59.4 ± 12.89 | 61.7 ± 12.18 |
| Sex: Female, Male(Participants) | Everolimus + BSC | Placebo+BSC | Total |
|---|---|---|---|
| Female | 116 | 44 | 160 |
| Male | 89 | 53 | 142 |
| Race/Ethnicity, Customized(Participants) | Everolimus + BSC | Placebo+BSC | Total |
|---|---|---|---|
| Caucasian | 162 | 68 | 230 |
| Asian | 32 | 18 | 50 |
| Black | 6 | 9 | 15 |
| Other | 5 | 2 | 7 |
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2012 to primary completion in Nov 2014, 31 months.
Results were first posted in Dec 2016, 2 years 1 month after primary completion.
Of 25 phase 3 interventional studies under Neuroendocrine Tumors, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 85. This study's 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus